Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Endoscopy, histology show limited utility in assessing ulcerative colitis disease activity

Tristan Manalac
24 Jan 2020

In patients with ulcerative colitis (UC), changes in histologic and endoscopic scores appear to be weakly to moderately predictive of each other, according to an analysis of the HICKORY study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).

“HICKORY is an ongoing phase III study evaluating etrolizumab in antitumor necrosis factor–experienced patients with moderate-to-severe UC,” said researchers. The present study aimed to uncover correlations between changes in histology and in disease activity measures in this open-label induction cohort.

Of the 97 enrolled participants, 22 percent (n=21) showed resolution of neutrophilic inflammation by week 14, defined as having a Nancy histologic index (NHI) score 1, or a Robarts histopathology index (RHI) score ≤3 with a Geboes subgrade rating of 2B.0/3.0. [AIBD, abstract P069]

At the same time point, 23 percent (n=22) were found to have endoscopic improvement, defined as a Mayo Clinic score (MCS) endoscopic subscore (ES) ≤1. Eight percent (n=8) had endoscopic remission. Twelve (55 percent) and six (75 percent) of these patients, respectively, showed neutrophilic resolution.

Spearman correlation analysis found that longitudinal changes in the NHI and RHI scores were strongly correlated with each other (ρ, 0.91). However, their interactions with other more established markers of disease activity were weaker in magnitude. Spearman coefficients between NHI, RHI or ES, for example, ranged from –0.02 to 0.38 for longitudinal changes in faecal calprotectin levels.

The same was true for changes in C-reactive protein (ρ, 0.03–0.07), albumin (ρ, –0.19 to –0.10), haemoglobin (ρ, –0.22 to –0.19) and segmented neutrophils in the blood (ρ, –0.06 to 0.01). Changes in RHI and NHI were both only weakly correlated with trends in ES, rectal bleeding and stool frequency.  

Notably, changes in the histologic (NHI and RHI/Geboes scores) and endoscopic (MCS ES) scores were likewise only weakly correlated with symptomatic outcomes, with ĸ coefficient values ranging from 0.28 to 0.45.

“As endoscopy and histology are both independent predictors of clinical outcomes in UC, there remains a need to assess these measures in parallel to demonstrate clinical benefit,” said the researchers. The present study found that overall, endoscopy and histology are weakly predictive of each other and of laboratory results after 14 weeks. Its ability to predict symptomatic manifestations is similarly weak.

However, comparing participant subgroups according to the achievement of change in MCS ≥3 from baseline, the researchers found minimum clinically important differences in NHI and RHI of 1.2 and 8.6, respectively.

This suggests that “both the NHI and RHI appear to effectively evaluate neutrophilic resolution, making the changes in score more clinically interpretable,” they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.